ETN005

ETN005 is a preclinical-stage small molecule drug candidate being developed by Shanghai ETERN Biopharma (also known as ETERN Therapeutics) for the treatment of solid tumors, specifically lung and breast cancer. The drug is part of a pipeline focused on modulating protein liquid-liquid phase separation (LLPS), a novel therapeutic approach aimed at targeting previously "undruggable" proteins. By utilizing a proprietary platform that integrates protein phase separation biology, AI-based target identification, and phenotypic screening, ETN005 is designed to influence the dynamics and intermolecular organization of proteins involved in oncogenic processes. While the specific molecular target has not been publicly disclosed, the drug represents a new class of therapeutics that disrupt or modulate the formation of biomolecular condensates associated with cancer progression.